Novocure Ltd is primarily active in the healthcare industry.

The main competitors of Novocure Ltd in the market include established companies such as Johnson & Johnson, Varian Medical Systems, and Accuray Incorporated.

Novocure Ltd is a renowned healthcare company specializing in the development and commercialization of innovative cancer treatment therapies. Established in 2000, Novocure focuses on utilizing Tumor Treating Fields (TTFields) to combat solid tumors. The company's first commercially approved product, Optune, has been proven effective in treating glioblastoma, an aggressive type of brain cancer. Novocure's extensive research and development efforts have led to several clinical trials and collaborations with leading medical institutions worldwide. By revolutionizing cancer therapy, Novocure Ltd is dedicated to improving the lives of patients and their families by offering a novel approach to fighting cancer.

Since its inception, Novocure Ltd has achieved numerous significant milestones. The company successfully developed and commercialized Optune, a breakthrough medical device for treating brain tumors. Novocure's endeavors have been acknowledged globally, with Optune gaining regulatory approvals in various countries, including the United States, Europe, and Japan. The company has had multiple successful clinical trials, proving the efficacy and safety of their innovative therapy. Novocure has also expanded its product portfolio, introducing Optune Lua for the treatment of malignant pleural mesothelioma. These milestones highlight Novocure Ltd's commitment to advancing treatment options and revolutionizing cancer care.

Novocure Ltd is primarily present in various countries and regions across the globe. The company has a significant presence in the United States, where it is headquartered. Additionally, Novocure operates in several European countries, including Germany, France, Italy, and the United Kingdom. The company also has a presence in Japan, as well as other Asian countries such as South Korea and Singapore. Furthermore, Novocure continues to expand its reach into new markets, demonstrating its commitment to establishing a global presence in the field of cancer treatment technologies.

Novocure Ltd represents a commitment to innovative cancer treatment. The company's corporate philosophy centers around providing patients with advanced therapies and improving their quality of life. Novocure focuses on developing and commercializing its proprietary tumor-treating fields (TTFields) technology, delivering electricity to disrupt cancer cell division. By merging science, engineering, and patient-centered care, Novocure aims to revolutionize cancer treatment and provide hope for patients. With a strong emphasis on research, development, and collaboration, Novocure strives to make a lasting impact in the fight against cancer.

Analysts currently set an average price target of 24,55 USD for the Novocure stock (median: 24,48 USD), implying +56,5 % versus the latest price. The consensus is based on 13 analyst ratings.

Novocure Analyytikkojen kursstavoitteet 2026

13 analysts currently rate the Novocure stock: 10 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Novocure to generate revenue of 725,79 M USD and earnings per share of −1,30 USD.

Novocure Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Novocure share trades at 13,58 EUR (15,69 USD).

The Novocure share (NVCR) is listed on 4 stock exchanges, including: NASDAQ (NVCR), Frankfurt (038.F), München (038.MU), Düsseldorf (038.DU).

Novocure Ltd is a biopharmaceutical company focused on the development and commercialization of proprietary therapies for the treatment of solid tumors. The company was founded in 2000 and is headquartered in Jersey, UK, with additional offices in the US, Germany, Japan, and Switzerland. Novocure's business model is based on the use of Tumor Treating Fields (TTF), a proprietary technology approach, through the use of Tumor Therapy Systems (TTS). TTF technology is a non-invasive method of cancer treatment that utilizes the application of electric fields to inhibit tumor growth. TTF technology is used in a portable device called Optune, which is approved as a medical device. Novocure's main product is the Optune System, currently used for the treatment of glioblastomas, a rare and hard-to-treat form of brain cancer. Optune is a portable device worn on the patient's head, generating electric fields to inhibit and slow down the growth of cancer cells. Treatment with Optune can extend the survival of patients with glioblastoma by several months and significantly improve their quality of life. In addition to Optune, Novocure is also working on the development of TTS systems for other types of cancer, including pancreatic cancer, lung cancer, and breast cancer. These products are currently in various stages of clinical development, and the company collaborates closely with researchers and clinicians to investigate the effectiveness of TTF technology in different types of cancer. Furthermore, Novocure has partnerships with various pharmaceutical companies to study the combination of TTF technology with other cancer drugs to enhance the effectiveness of chemotherapy. The company is also working on the development of TTS systems for the treatment of neurological disorders such as Alzheimer's and Parkinson's. Overall, Novocure's business model focuses on the development and commercialization of therapies for the treatment of solid tumors, with emphasis on TTF technology and the Optune System. The company also pursues a broader strategy of exploring new markets and applications for the technology, including collaborations with other companies and research institutions.

odotettu liikevaihto Novocure on 725,79 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Novocure on −145,24 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Novocure:n hinta-voitto-suhde (P/E) on tällä hetkellä −12,04. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Novocure-osakkeen arvostusta.

Novocure:n hinta-myynti-suhde (P/S) on tällä hetkellä 2,41. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Novocure-osakkeen arvostuskennuslukuna.

Novocure:n Eulpool-laatuscore on 3/10.

Novocure:n ISIN on JE00BYSS4X48. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Novocure:n WKN on A140ML. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Novocure:n ticker on NVCR. Tämä pörssinoteeraus käytetään Novocure-osakkeiden kauppaan pörssissä.

Novocure maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Novocure kuuluu sektoriin 'Terveydenhuolto'.

Novocure:n osingot jaetaan valuutassa USD.